The German pharmaceutical and life sciences company reported first-quarter earnings that topped consensus
Bayer revealed an EPS of €2.59, beating the €2.47 forecast. At the same time, the revenue figures came in at $12.33 billion, higher than the €12 billion initially touted.
The company’s free cash flow plummeted to -€3.23 billion, from last year’s -€793 million. The plunge was caused by the settlement payments for litigations involving its Roundup pesticide.
For the entire 2021, Bayer expects sales to clock between €42 billion and €43 billion., in line with its previous outlook.
After the news hit the wires, Bayer stock price went up almost 5%. Since the beginning of the year, its shares are up 16%.
Sources: investing.com, marketwatch.com
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of sc.capex.com